Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant <i>Klebsiella Pneumoniae</i>: Exploring A Colistin Sparing Protocol

• Príomhchruthaitheoirí: Manawr AL-Quraini (Údar), Meher Rizvi (Údar), Zaaima AL-Jabri (Údar), Hiba Sami (Údar), Muna AL-Muzahmi (Údar), Zakariya AL-Muharrmi (Údar), Neelam Taneja (Údar), Ibrahim AL-Busaidi (Údar), Rajeev Soman (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2022-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Fosfomycin has emerged as a very useful antimicrobial in management of extremely drug resistant (XDR) and pan drug resistant (PDR) <i>Klebsiella pneumoniae</i>. In this study, we assessed in-vitro synergy of colistin sparing combinations of fosfomycin (FOS) with meropenem (MEM), tigecycl...